Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Phi Sciences
WARNING LETTER
•Phi Sciences•August 18, 2018

FDA WARNING_LETTER - Phi Sciences - August 18, 2018

View on Dashboard

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Phi Sciences
Record Details

The FDA conducted an inspection of Phi Sciences in Cottonwood, Arizona, from August 10-18, 2018. The inspection, product labels, and website review revealed serious violations of the Federal Food, Drug, and Cosmetic Act.

The products Mega Hydrate Powder, Mega Hydrate Capsules, and Crystal Energy are deemed unapproved new drugs because website claims and testimonials indicate their intended use for disease cure, mitigation, treatment, or prevention. These products are not generally recognized as safe and effective, lacking FDA approval. Furthermore, they are misbranded as they fail to bear adequate directions for use, being intended for conditions not amenable to self-diagnosis or treatment.

Additionally, these products are adulterated dietary supplements due to Current Good Manufacturing Practice (CGMP) violations. The company failed to establish and follow written procedures for quality control operations (21 CFR 111.103) and for holding and distributing operations (21 CFR 111.453). The firm's October 5, 2018, response regarding creating a procedure manual was deemed insufficient.

The products are also misbranded dietary supplements due to various labeling deficiencies, including failing to list the manufacturer's name and place of business (21 CFR 101.5), incorrect net quantity of contents for Mega Hydrate Powder (21 CFR 101.7(b)(1)), incorrect serving size declarations (21

Company
Phi Sciences
Inspection Date
August 18, 2018
Product Type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Latonya Mitchell (District Director)
  • Jessica Oates
Open in Dashboard

ID · 2ba1226b-0873-4b1f-8e53-3edd2c02325f

Violation Codes10
21 U.S.C. 321(g)(1)(B)21 U.S.C. 321(p)(1)21 U.S.C. 331(d)21 U.S.C. 355(a)21 U.S.C. 352(f)(1)21 U.S.C. 331(a)21 U.S.C. 342(g)(1)21 CFR 11121 CFR 111.10321 CFR 111.55

Full citation text and observation details available on the Dashboard.

KeyPedia
Regulatory Data Transformed
Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@globalkeysolutions.net
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.